Halozyme Therapeutics, Inc. has announced that the European Commission has granted marketing authorization to Roche for OCREVUS® SC, a subcutaneous formulation of ocrelizumab co-formulated with Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20 (ENHANZE®). This approval allows for the treatment of both relapsing multiple sclerosis and primary progressive multiple sclerosis in the European Union.
The combination of OCREVUS® with ENHANZE® enables the subcutaneous administration of the medication, offering a more convenient and less time-consuming alternative to the traditional intravenous infusion. This innovative approach to drug delivery has the potential to improve patient compliance and quality of life for those living with multiple sclerosis.
